Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 10/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL14672693 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL14672704 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL4592445 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL14735852 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL3257950 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL459208 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL14672707 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL19469979 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL1493337 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Chloroform SCHEMBL1724110 | 1.00 | TSHR (0.42) | TSHRTHRBFDPSSMPD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084171-B1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO KK (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20090315454-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO K.K. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2084171-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | Showa Denko K.K. (JP) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056799-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO K.K. (JP) | 2008-05-15 | — | — | WO | disclosed |
| US-20080050604-A1 | Polymer Light-Emitting Material and Organic Light Emitting Element | SHOWA DENKO K.K. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-6835471-B2 | Discotic liquid crystal compounds using a multifunction porphyrin derivative compound which is light-emissive and especially has phosphorescent light emission properties and liquid crystal properties simultaneously | CANON KABUSHIKI KAISHA (JP) | 2004-12-28 | — | — | US | disclosed |
| US-20030034722-A1 | Light emitting device and display unit which make use of porphyrin derivative compound | CANON KABUSHIKI KAISHA (JP) | 2003-02-20 | — | — | US | disclosed |
| US-6150363-A | INHIBITORY AGENT OF GLUTAMIC ACID TOXICITY WHICH CONTAINS A DIHYDROPHENAZINECARBOXYLIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0945444-A1 | DIHYDROPHENAZINECARBOXYLIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5834575-A | POLYIMIDE OR POLYACRYLATE WITH PENDANT GROUP CONTAINING THIOPHENE RING, BENZENE RING AND VICINAL NITRILE GROUPS, SWITCHES FOR OPTICAL SIGNALS, COMMUNICATION TECHNOLOGY | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5308848-A | Side effect reduction | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0452107-A1 | Pyrimidinedione derivatives and antiarrythmic agents containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4916058-A | CHROMOGENS | KYOWA MEDEX CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090315454-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | ELP1, RUVBL1, LIG1 | TSHR 1790/4885THRB 4315/4885FDPS 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.